On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...